Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Waldenstrom Macroglobulinemia 1Non-Melanoma Skin Carcinoma 1Lymphoma, Mantle-Cell 1Lymphoma, Follicular 1Lymphoma, B-Cell, Marginal Zone 1Leukemia, Myeloid, Acute 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leukemia 1Invasive Fungal Infections 1Haematological Malignancies 1Carcinoma, Hepatocellular 1B-cell Malignancies 1

Interventions

Rituximab 23Lenalidomide 11Cyclophosphamide 10zanubrutinib 9Bendamustine Hydrochloride 8venetoclax 6ibrutinib 6fludarabine 6parsaclisib 5idelalisib 5ublituximab 4obinutuzumab 4aflibercept 4Prednisone 4pirtobrutinib 3Vincristine 3ME-401 3Doxorubicin 3umbralisib 2tazemetostat 2marizomib 2epratuzumab 2Radioimmunodetection 2voruciclib 1veltuzumab 1varlilumab 1tislelizumab 1tetulomab tetraxetan lu-177 1tafasitamab 1repaglinide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Lymphoma, B-Cell, Marginal Zone × Voriconazole × Clear all
NCT02381080 2017-06-26

Interaction Study of Ibrutinib and Cytochrome P450 (CYP) 3A Inhibitors in Participants With B-cell Malignancy

Janssen Research & Development, LLC

Phase 1 Completed
26 enrolled
LymphoidOther hematologic neoplasm

Lymphoma, Follicular, Waldenstrom Macroglobulinemia, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡